Coeptis Therapeutics Holdings, Inc.

NasdaqCM:COEP Stock Report

Market Cap: US$7.8m

Coeptis Therapeutics Holdings Valuation

Is COEP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COEP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate COEP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate COEP's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for COEP?

Key metric: As COEP is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for COEP. This is calculated by dividing COEP's market cap by their current book value.
What is COEP's PB Ratio?
PB Ratio1.7x
BookUS$4.82m
Market CapUS$7.81m

Price to Book Ratio vs Peers

How does COEP's PB Ratio compare to its peers?

The above table shows the PB ratio for COEP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.3x
EDSA Edesa Biotech
2.5x-32.7%US$6.9m
ENZN Enzon Pharmaceuticals
2xn/aUS$5.3m
TSBX Turnstone Biologics
0.3x-11.6%US$10.9m
APTX Aptinyx
0.4xn/aUS$6.5m
COEP Coeptis Therapeutics Holdings
1.7x-13.7%US$7.8m

Price-To-Book vs Peers: COEP is expensive based on its Price-To-Book Ratio (1.7x) compared to the peer average (1.3x).


Price to Book Ratio vs Industry

How does COEP's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
ACET Adicet Bio
0.4x6.7%US$75.31m
MGX Metagenomi
0.3x-23.2%US$68.11m
COEP 1.7xIndustry Avg. 1.8xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: COEP is good value based on its Price-To-Book Ratio (1.7x) compared to the US Biotechs industry average (1.8x).


Price to Book Ratio vs Fair Ratio

What is COEP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COEP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate COEP's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies